Efficacy and Safety of Dupilumab in Atopic Dermatitis
Research highlights the need for diverse data on drug efficacy in atopic dermatitis to address barriers to treatment for patients with skin of color, notes Elaine Siegfried, MD.
At the 34th Annual Congress of the European Academy of Dermatology and Venereology (EADV), research was presented on "Dupilumab Safety and Efficacy Up to 3 Years Across Racial Subgroups in Pediatric Patients Aged 6 Months to 11 Years With Atopic Dermatitis."
- By week 152 of an open-label extension analysis of dupilumab (NCT02612454) (Dupixent; Sanofi/Regeneron), treatment resulted in "consistent decreases in disease signs and symptoms" for both White and non-White patient groups.
consistent decreases in disease signs and symptoms
Author summary: Dupilumab shows efficacy in pediatric atopic dermatitis patients.
More News
- Breaking down the Week 14 Dolphins inactive info: Good news all around
- B.C. peacocks spared from avian flu cull
- Susan Dell sparks surgery rumors as experts estimate
- Éminent -Imminent. Quelle différence ?
- Inside Susan Dell's $50k MAGA makeover as many ask what happened
- Lexus Supercar Teased Ahead of Imminent Debut
- “The Night Agent” Season 3 Release Date
- TWU Local 234 leaders warn SEPTA strike is imminent
- Navjot Singh Sidhu CM-face remark and political comeback
- CNN: News and Updates